Harel Insurance Investments & Financial Services Ltd. Nektar Therapeutics Transaction History

Harel Insurance Investments & Financial Services Ltd.

$5.31 Billion
Q2 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 29, 2019	SELL	$30.43 - $56.65 $14,362 - $26,738	-472 Closed	0 $0
Q3 2018 Oct 29, 2018	SELL	$46.46 - $68.49 $743 - $1,095	-16 Reduced 3.28%	472 $26,000
Q1 2018 Apr 30, 2018	BUY	$57.4 - $108.44 $28,011 - $52,918	488 New	488 $52,000

Others Institutions Holding NKTR

# of Institutions

126

Shares Held

109M

Call Options Held

150K

Put Options Held

Deep Track Capital, LP Greenwich, CT

18.4M
Shares

$25.4 Million
0.57% of portfolio
Vanguard Group Inc Valley Forge, PA

12M
Shares

$16.6 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

7.57M
Shares

$10.4 Million
0.02% of portfolio
Primecap Management CO Pasadena, CA

6.97M
Shares

$9.61 Million
0.0% of portfolio
Black Rock Inc. New York, NY

5.88M
Shares

$8.11 Million
0.0% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harel Insurance Investments & Financial Services Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Harel Insurance Investments & Financial Services Ltd. with notifications on news.

Account